Singh HK, Patil V, Chaitanya G, Nair D. Preparedness of the cancer hospitals and changes in oncosurgical practices during COVID‐19 pandemic in India: A cross‐sectional study. J Surg Oncol. 2020;1--12. 10.1002/jso.26174

1. INTRODUCTION {#jso26174-sec-0050}
===============

Coronavirus disease‐2019 (COVID‐19) pandemic has resulted in over 0.9 million cases and over 23 000 deaths in India as on 14th July 2020.[^1^](#jso26174-bib-0001){ref-type="ref"} India was under a total lockdown for 68 days from 24th March 2020. This had an unprecedented effect on the health care system, especially on oncological care as resources were reallocated to patients with COVID‐19.[^2^](#jso26174-bib-0002){ref-type="ref"} The routine challenges in the management of cancers include: difficulties in managing aggressive malignancies resulting in comparatively higher mortality rates (3%‐7%)[^3^](#jso26174-bib-0003){ref-type="ref"}; prolonged time‐to‐initiate‐treatment affecting survival and increasing anxiety among patients[^4^](#jso26174-bib-0004){ref-type="ref"} and finally a long drawn course of oncological treatment, that can get significantly affected during the pandemic. The resultant immune suppression[^5^](#jso26174-bib-0005){ref-type="ref"} poses a greater risk to COVID‐19 infection, more so if they have received treatment within the previous month.[^6^](#jso26174-bib-0006){ref-type="ref"} An estimated 192 000 patients are likely to have delays in the timely diagnosis of cancer as projected by the Indian Council of Medical Research,[^7^](#jso26174-bib-0007){ref-type="ref"} adding to the backlog of patients who await treatment at many oncology institutes. With a mere 2.2% of the gross domestic product being invested in public health,[^8^](#jso26174-bib-0008){ref-type="ref"}, [^9^](#jso26174-bib-0009){ref-type="ref"} a country like India with a population of more than 1.3 billion will have to surmount the challenge of controlling the pandemic and restoring cancer care to normalcy. This study aims to understand how rapidly the oncology hospitals adapted to the pandemic and the needs of the patients to provide for the necessary oncology services particularly with regards to surgery for cancer and preparedness of the hospitals across the various cities and importantly COVID‐19 zones.

Oncosurgical care during the pandemic was assessed based on (a) preparedness of the hospital by establishment of COVID‐19 screening clinics, COVID‐19 wards/committees/intensive care units (ICUs)/operating rooms (OR), (b) major and minor surgeries being performed, and (c) employee well‐being determined by deductions in salary, provisions for paid leave and to work in‐rotation. We compared these across geographical hospitals (ie, COVID‐19 lockdown zones and city tier) and administrative organization of the facility (ie, government vs private, academic vs nonacademic, and dedicated hospitals vs multispecialty hospitals).

2. MATERIALS AND METHODS {#jso26174-sec-0060}
========================

Oncosurgeons (consisted of surgical oncologists, gynec‐oncologists, and head and neck oncosurgeons) practicing in India across various oncology hospitals were invited to participate in an anonymous online questionnaire‐based cross‐sectional study (Supplemental File 1), between 18 and 27th May 2020 (during the nationwide lockdown), where the data were collected with no identifiers recorded from the participating individuals. Participants were recruited through social networking websites, personal messages, and emails. The questionnaire was designed to include sections on (a) demography, (b) hospital preparedness, (c) surgical practices, and (d) remarks section to record the issues not covered by the survey.

Definitions used in the survey regarding lockdown zones,[^10^](#jso26174-bib-0010){ref-type="ref"} adequate personal protective equipment[^11^](#jso26174-bib-0011){ref-type="ref"} (PPE), and major surgeries are as shown in Table [1](#jso26174-tbl-0001){ref-type="table"}. The cities were classified as tier‐1, 2, and 3.[^12^](#jso26174-bib-0012){ref-type="ref"}

###### 

Definitions used in manuscript

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Red zone                                                                                                                                                                                     Red zones/hot spots are defined by taking into account the number of active of cases, doubling the rate of confirmed cases, extent of testing, and surveillance feedback. There is severe restriction of activity of the people that live within the defined zone.
  Orange zone                                                                                                                                                                                  Red zones are converted to orange after there are no new cases for at least 21 days. Some movement with social distancing norms is allowed with caution so as to limit the spread of coronavirus in this area.
  Green zone                                                                                                                                                                                   Area defined by the absence of any confirmed cases or an orange zone that has not reported any new cases for 21 days. May allow movement with due caution so that area remains COVID‐19 free. Mild restriction of activities with social distancing are to be followed so that the area remains COVID‐19 free.
  Major oncologic surgery                                                                                                                                                                      Requiring at least one of the following: postoperative ICU care and monitoring, blood loss more than 400 mL or requiring multiple transfusions, or performing soft tissue reconstruction.
  Adequate PPE                                                                                                                                                                                 As PAPR or single use N95 mask and goggles or face shield, impermeable gown with double gloves be needed as a minimal adequate PPE for high‐risk/aerosolizing procedure.
  HIV Kit (single use only)                                                                                                                                                                    Has the following:
  Gown that is disposable, sterile, made up fabric that is impervious to blood and body fluids. This kit also has a surgical cap, surgical mask, goggles, two pairs of gloves, and leggings.   
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: COVID‐19, coronavirus disease‐2019; HIV, human immunodeficiency virus; ICU, intensive care units; PPE, personal protective equipment; PAPR, powered air‐purifying respirators.
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We assessed the following in the survey 1.Hospital preparedness determined by the establishment of screening procedures for COVID‐19 and dedicated committees/wards/ICUs/ORs for COVID‐19.2.The proportion of oncosurgeons providing continued care with required major and minor surgeries during the pandemic.3.The proportion of oncosurgeons reporting deduction in salaries, provision for paid leave and to work in rotation with colleagues, as a measure of employee well‐being.4.The proportion of oncosurgeons who experienced a difficulty in (a) getting investigations for staging cancers, (b) finding gastroenterologists for endoscopy/microvascular surgeon, and (c) the availability of PPE.5.The proportion of oncosurgeons who had to defer (a)surgery after a good response to neoadjuvant chemotherapy (NACT), (b) radiotherapy (RT)/chemotherapy if there is only marginal benefit to patients, and (c) treatment for preinvasive diseases.6.The aforementioned changes in oncosurgical practice were finally compared among different geographical hospitals (ie, COVID‐19 lockdown zones and city tier) and administrative organization of the facility (ie, government vs private, academic vs nnonacademic, and dedicated hospitals vs multispecialty hospitals).

2.1. Statistical analysis {#jso26174-sec-0070}
-------------------------

All responses were grouped into categorical variables (nominal or ordinal). Once the responses were paired, the data were analyzed using *χ* ^2^ tests to answer the pertinent questions. Conditional formatting was used to sort layered responses. Two‐tailed *P* \< .05 was considered significant.

3. RESULTS {#jso26174-sec-0080}
==========

Of the 480 oncosurgeons, 256 (53.3%) from 206 hospitals in 85 cities completed the survey. Ten oncosurgeons declined participation (five had their hospital completely shut down due to pandemic; three worked in set‐ups with limited beds; and two were on maternity leave). The mean age was 37 ± 7years, (range, 31‐66 years). The demographic details are enumerated in Table [2](#jso26174-tbl-0002){ref-type="table"}.

###### 

Demographic details

  Age                                                  39 ± 7 y (range, 31‐66 y)   
  ---------------------------------------------------- --------------------------- -------------
  Gender                                               Male                        226 (88.3%)
  Female                                               30 (11.7%)                  
  Surgical oncology subspecialties                     Surgical oncology           213 (83.2%)
  Head and neck oncology                               24 (9.4%)                   
  Gynec‐oncology                                       19 (7.4%)                   
  City                                                 Tier 1                      99 (48.1%)
  Tier 2                                               76 (36.9%)                  
  Tier 3                                               31 (15%)                    
  Type of sector                                       Government                  26 (12.6%)
  Private                                              159 (77.2%)                 
  Mixed government and private sector                  6 (2.9%)                    
  Nongovernment organization/charitable organization   15 (7.3%)                   
  Academic center                                      Yes                         117 (56.8%)
  No                                                   89 (43.2%)                  
  Hospital set up                                      Dedicated oncology          67 (32.5%)
  Oncology with other specialties                      139 (67.5%)                 
  Zones                                                Red                         117 (56.8%)
  Orange                                               64 (31.1%)                  
  Green                                                25 (12.1%)                  
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3.1. Adaptation of hospitals to pandemic {#jso26174-sec-0090}
----------------------------------------

Hospitals adopted organizational changes to combat the pandemic. Routine screening for COVID‐19 infection included temperature, symptom check, and detailed contact history before entry into the hospital (98% of the hospitals). Dedicated COVID‐19 committee to streamline operations were formed in 73.7% of the hospitals. Dedicated COVID‐19 ward, ICU, and OR for patient care were established in 67.3%, 49%, and 36% of the hospitals, respectively. Such preparedness was higher in hospitals in tier‐1 cities, government, and academic institutes (Table [3](#jso26174-tbl-0003){ref-type="table"}).

###### 

General hospital organization and major surgeries

                                             Numbers      Tier‐1 vs tier‐2 vs tier‐3 (n \[%\], *P* value)   Government vs private vs mixed sector vs NGO (n \[%\], *P* value)   Academic vs nonacademic center (n (%), *P* value)   Red zone vs orange vs green zones (n \[%\], *P* value)   Dedicated cancer vs multispecialty center (n \[%\], *P* value)
  ------------------------------------------ ------------ ------------------------------------------------- ------------------------------------------------------------------- --------------------------------------------------- -------------------------------------------------------- ----------------------------------------------------------------
  Hospital organization (N = 206)                                                                                                                                                                                                                                                            
  COVID screening                            202 (98.1)   97 (98) vs 75 (98.7) vs 30 (96.8) *P* = .8        26 (100) vs 156 (98.1) vs 6 (100) vs 14 (93.3) *P* = .49            116 (99.1) vs 86 (96.6), *P* = .19                  114 (97.4) vs 64 (100) vs 24 (96), *P* = .35             65 (97) vs 137 (98.6), *P* = .45
  COVID committee                            151 (73.7)   78 (78.8) vs 56 (73.7) vs 17 (56.7), *P* = .01    26 (100) vs 109 (69) vs 4 (66.7) vs 12 (80), *P* = .05              102 (87.2) vs 49 (55.7), *P* \< .001                90 (76.9) vs 40 (63.5) vs 21 (84), *P* = .067            46 (69.7) vs 105 (75.5), *P* = .128
  COVID ward                                 136 (67.3)   74 (76.3) vs 46 (60.5) vs 16 (55.2), *P* = .10    20 (76.9) vs 104 (66.7) vs 4 (80) vs 5 (53.3), *P* = .71            95 (81.9) vs 41 (47.7), *P* \< .001                 79 (68.1) vs 39 (62.9) vs 18 (75), *P* = .59             30 (45.5) vs 106 (77.9), *P* \< .001
  COVID ICU                                  99 (49)      64 (66) vs 26 (34.7) vs 9 (30), *P* \< .001       15 (57.7) vs 76 (49) vs 4 (66.7) vs 4 (26.7), *P* = .09             75 (64.7%) vs 24 (27.9), *P* \< .001                62 (53.4) vs 25 (40.3) vs 12 (50), *P* = .56             12 (18.2) vs 87 (64), *P* \< .001
  COVID ORs                                  68 (36)      43 (46.7) vs 20 (28.2) vs 5 (19.2), *P* = .008    11 (42.3) vs 51 (35.2) vs 2 (40) vs 4 (30.8), *P* = .8              55 (50) vs 13 (16.3), *P* \< .001                   41 (39) vs 18 (29.5) vs 9 (39.1), *P* = .44              14 (21.9) vs 54 (43.2), *P* = .004
  Major surgeries peformed by oncosurgeons                                                                                                                                                                                                                                                   
  Breast oncology                            109 (52.4)   50 (49) vs 42 (56.8) vs 17 (53.1), *P* = .08      10 (35.7) vs 85 (53.8) vs 3 (60) vs 11 (64.7), *P* = .015           63 (53.4) vs 46 (51.1), *P* = .152                  65 (53.3) vs 35 (58.3) vs 9 (34.6), *P* = .19            38 (50.7) vs 71 (53.4), *P* = .7
  Head neck oncology                         178 (76.7)   81 (72.3) vs 68 (84) vs 29 (74.4), *P* = .39      22 (62.9) vs 137 (79.2) vs 5 (83.3) vs 14 (77.8), *P* = .020        105 (77.2) vs 75 (76), *P* = .41                    102 (75) vs 54 (79.4) 22 (78.6), *P* = .94               72 (88.9) vs 106 (70.2), *P* = .006
  Colorectal oncology                        168 (80.8)   80 (78.4) vs 60 (81.1) vs 28 (87.5), *P* = .26    20 (71.4) vs 131 (82.9) vs 4 (80) vs 13 (76.5), *P* = .42           91 (77.1) vs 77 (85.6), *P* = .30                   99 (81.1) vs 48 (80) vs 21 (80.8), *P* = .769            67 (89.3) vs 101 (75.9), *P* = .041
  Gynec‐oncology                             182 (80.2)   87 (77.7) vs 66 (80.5) vs 29 (87.9), *P* = .002   29 (70.3) vs 135 (80.8) vs 5 (83.3) vs 16 (94.1), *P* = .4          107 (79.9) vs 75 (80.6), *P* = .47                  104 (78.8) vs 56 (83.6) vs 22 (78.6), *P* = .83          69 (86.3) vs 113 (76.9), *P* = .187
  HPB                                        128 (61.5)   70 (68.6) vs 39 (52.7) vs 19 (59.4), *P* = .26    17 (60.7) vs 93 (58.9) vs 5 (100) vs 13 (76.5), *P* = .34           78 (66.1) vs 50 (55.6), *P* = .15                   76 (62.3) vs 36 (60) vs 16 (61.5), *P* = .167            51 (68) vs 77 (57.9), *P* = .139
  Thoracic oncology                          120 (57.7)   61 (59.8) vs 40 (54.1) vs 19 (59.4), *P* = .71    16 (57.1) vs 89 (56.3) vs 4 (80) vs 11 (64.7), *P* = .62            76 (64.4) vs 44 (48.9), *P* = .08                   71 (58.2) vs 32 (53.3) vs 17 (65.4), *P* = .55           48 (64) vs 72 (54.1), *P* = .38

Abbreviations: COVID, coronavirus disease; HPB, hepato‐pancreato‐biliary; ICU, intensive care units; NGO, nongovernment organization; ORs, operating rooms.
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3.2. Impact on routine outpatient services {#jso26174-sec-0100}
------------------------------------------

This pandemic has impacted the evaluation of patients and the delivery of care in outpatient clinics. Almost 50% of the oncosurgeons had suspended cancer screening, more in tier‐1 (56.9% vs 35.9%, *P* = .03), and red zones (57.1% vs 32.1%, *P* = .005) as compared with tier‐3 and green zones while 80.6% continued cancer surveillance in patients. Follow‐up consultations (72.2%) were done by telemedicine. Higher proportion of oncosurgeons in tier‐1 compared with other cities (79.8% vs others, *P* = .028), private hospitals (76.5% vs 61.4%, *P* = .015), and multispecialty hospitals (80.4% vs 56%, *P* \< .001) used telemedicine. Newly diagnosed cancers were continued to be evaluated by most of the oncosurgeons (96.1%) (Figure [1A](#jso26174-fig-0001){ref-type="fig"} and Supplemental File 2).

![A, OPD practices, oncology practices, and employee welfare. B, Provisions at the radiotherapy (RT) centers. C, Oncological subspecialties: major and minor surgeries. COVID‐19, coronavirus disease‐2019; NACT, neoadjuvant chemotherapy; OPD, outpatient department \[Color figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)\]](JSO-9999-na-g001){#jso26174-fig-0001}

3.3. Investigations for staging cancers {#jso26174-sec-0110}
---------------------------------------

Oncosurgeons reported difficulty in obtaining investigations (ie, computed tomography \[CT\], magnetic resonance imaging, or positron emission tomography) for staging cancers (70%) during the lockdown. Gastroenterologists were unavailable for endoscopies (68.7%). Oncosurgeons were compelled to consider surgery for inadequately staged patients (16%). All lockdown zones were equally affected by such concerns (Supplemental File 2).

3.4. PPEs for oncosurgeons and surgical teams during high‐risk surgeries {#jso26174-sec-0120}
------------------------------------------------------------------------

Oncosurgeons are faced with the problem of inadequate supply of PPEs. Oncosurgeons used N95 respirators (94.2%) or surgical masks (78.1%) or powered air‐purifying respirators (PAPR; 28.9%) for respiratory protection. However, the exclusive use of these was very infrequent (N95: 15%, surgical masks: 4.2%, and PAPR \< 1%). Oncosurgeons used gowns designed either for COVID‐19 (51.7%) or HIV protection kit (Table [1](#jso26174-tbl-0001){ref-type="table"}) (73.2%) or regular surgical gowns (56.5%). Exclusive use of the three suit designs was also infrequent (COVID‐19 suits: 11.7%, HIV kit gowns: 18%, and regular surgical gowns: 11%). PAPR and gown designed for COVID‐19 were used more often in tier‐1 cities compared with tier‐2/3 (PAPR: 36.4% vs 20% vs 27.8%, *P* = .04; COVID gowns: 58.3% vs 39.3% vs 59.5%, *P* = .018). Face shields to protect from aerosols were used by 90% of oncosurgeons, particularly in red zones compared with orange/green (93.7% vs 87.5% vs 80%, *P* = .049) (Supplemental File 2).

Oncosurgeons reported adequate availability of PPE among their colleagues in anesthesia (88.3%), scrub nurses (86.7%), and surgical assistants (89.1%). We specifically did not collect information on which component was unavailable. Tier‐3 cities, nonacademic institutions, and green zones as compared with tier‐1, academic institutes, and red zones did not have an adequate supply of PPE for the surgical team (Supplemental File 2).

3.5. Preoperative testing and oncological surgeries {#jso26174-sec-0130}
---------------------------------------------------

Routine preoperative COVID‐19 testing was practiced by 57.9% of oncosurgeons. Testing was done more frequently in the tier‐1 (80%, *P* \< .001), academic (62.6%, *P* = .05), red zones (63.5%, *P* = .06), and multispecialty hospitals (*P* = .013) as compared with tier‐3, nonacademic, green zones, and dedicated hospitals. Almost 80% of oncosurgeons continued major surgeries across all subspecialties of oncology but for hepato‐pancreato‐biliary (HPB), thoracic oncology, and cytoreductive surgeries (CRS)/hyperthermic intraperitoneal chemotherapy (HIPEC), which were reduced to 61%, 57%, and 32%, respectively (Figure [1C](#jso26174-fig-0001){ref-type="fig"}). Dedicated oncology hospitals (74.1% vs 44.1%, *P* \< .001) and hospitals in green zones (60% vs 44.5%, *P* = .023) continued their elective cancer surgeries compared to multispecialty hospitals and red zones despite the lockdown, respectively. These dedicated hospitals continued more surgeries across all subspecialties, particularly in head and neck (HN) (88.9% vs 70.2%, *P* = .006), and colorectal oncology (89.3% vs 75.9%, *P* = .04) more than multispecialty hospitals. Oncosurgeons preferred open surgeries (64.1%) over minimally invasive surgeries (MIS) (10%), particularly more in surgeons practicing in tier‐3 compared with tier‐1 (75% vs 59.6%, *P* = .043). Only 60% of oncosurgeons continued to perform microvascular reconstruction. A higher proportion of private hospitals performed microvascular reconstruction more than government hospitals (63.9% vs 40.7%, *P* = .017), while the practice of pedicle flaps over free flaps did not differ with hospitals. However, the decision to perform a tracheostomy was the same across all oncosurgeons and was determined by the extent of primary resections. The types and extent of surgeries performed did not differ between the tier of the city and zones (Table [1](#jso26174-tbl-0001){ref-type="table"} and Supplemental File 2)

3.6. Adjuvant and neoadjuvant treatment and facilities available at the RT units {#jso26174-sec-0140}
--------------------------------------------------------------------------------

Those patients in whom tumor showed a good response to NACT, surgeries were deferred by 38.4% of oncosurgeons due to fear of patients contracting COVID‐19 infection. Dedicated cancer institutes preferred surgery after NACT more often compared with multispecialty hospitals in patients who completed all cycles of chemotherapy (73.2% vs 55.6%, *P* = .008) (Figure [1A](#jso26174-fig-0001){ref-type="fig"}).

Oncosurgeons (32.3%) deferred/avoided adjuvant treatment (RT and chemotherapy) if only a marginal benefit was expected while the risk of contracting COVID‐19 was higher for the patients. This was majorly practiced more often in government hospitals (51.3% vs 27.8%, *P* = .03)

Treating preinvasive disease was at a low priority among oncosurgeons (60.7%), majorly in the government hospitals compared with private (76.9% vs 57.3%, *P* = .058) and hospitals in red zones (61.5% vs 38.5%, *P* = .03)

Oncosurgeons reported shut down (5.1%) and increased waitlist (26.9%) at RT units, particularly in government institutes and tier‐3 cities. Dedicated hospitals particularly used hypofractionated regimens (40% vs 32.8%, *P* = .05) and delivered palliative RT (88.4% vs 73.9%, *P* = .016) to the patients as compared with multispecialty hospitals. Private hospitals also continued providing palliative RT for the metastatic patients compared to the government hospitals (82% vs 68.3%, *P* = .038) (Supplemental File 2 and Figure [1B](#jso26174-fig-0001){ref-type="fig"}).

3.7. Care for palliative patients/stage‐IV and psychological impact on patients {#jso26174-sec-0150}
-------------------------------------------------------------------------------

Oncosurgeons reported that their patients were anxious (60%) about getting the appropriate treatment during the pandemic. This concern was higher in tier‐3 cities (77.1% vs 60.5%, *P* = .029) and government hospitals (82.7% vs 55.4%, *P* = .006). Oncosurgeons also felt that stage‐IV patients/palliative patients may not get the appropriate care (32.2%), particularly in government (47.6% vs 29.3%, *P* = .07) and tier‐3 hospitals (46.2% vs 28.3, *P* = .11).

3.8. Employee well‐being {#jso26174-sec-0160}
------------------------

Oncosurgeons in private hospitals (54%) reported salary cuts ranging from 10% to 95% (\<20% deduction: 6.4%, 20%‐50% deduction: 21.4%, \>50%: 22.5%) working in the private hospitals (*P* \< .001) while 34.1% were affected in the government hospitals. Oncosurgeons (68%) had the provision of transportation to work, more in academic hospitals as compared with nonacademic hospitals (72.7% vs 60.8%, *P* = .004). Oncosurgeons were allowed to work in rotation (47%), particularly in tier‐1 cities (58.7% vs others, *P* = .003), in government hospitals (71% vs others, *P* = .001) (Supplemental File 2 and Figure [1A](#jso26174-fig-0001){ref-type="fig"}).

4. DISCUSSION {#jso26174-sec-0170}
=============

The results of this study indicate that there were major setbacks to cancer care in tier‐1 cities and these hospitals had adopted strategies to combat the pandemic. Hospitals in red zone deferred more surgeries in response to NACT, deferred RT/chemotherapy if only marginal benefit and treatment of preinvasive diseases than in the green zones. The nature of surgeries was not influenced by red zones. Complex reconstruction and use of technologies were seen more in private hospitals, government hospitals had better preparedness and preserved employee welfare while dedicated hospitals continued better comprehensive care.

Due to widespread lockdown in the country, the oncologists faced difficulty to adequately stage cancers. Scan centers may be overwhelmed especially in tier‐1 cities and red zones in India due to the nonavailability of the technicians, radiology staff, radioisotopes, and fewer functioning CT machines. Private hospitals and nonacademic hospitals had more problems in imaging indicating the huge reliance of these hospitals on the diagnostic centers. Kamarajah et al[^13^](#jso26174-bib-0013){ref-type="ref"} also reported similar problems in staging in treating esophagogastric cancers.

While oncology has been prioritized over non‐oncologic diseases, most of the guidelines have not addressed the issues regarding staging investigations. With India entering into a phase of community transmission, staging may become more difficult.

Historically, the International Federation of Gynecology and Obstetrics staging[^14^](#jso26174-bib-0014){ref-type="ref"} used in gynecology malignancies is predominantly based on clinical examination. Similar staging may be considered for cancers at sites amenable for detailed clinical examination like oral cavity, breast, and so forth when there is limited radiological/pathological backing after a multidisciplinary discussion.

Considering surgery for inadequately staged patients can have an impact on prognosis and further treatment, shared decision making with the patients and relatives may help to balance the risk‐benefit ratio.

Preoperative COVID‐19 testing has not been recommended in many guidelines given low the positive predictive value of swab testing is 47.3% to 84.3%.[^15^](#jso26174-bib-0015){ref-type="ref"} Hence, standard precautions are mandatory even if the patient tests negative. However, a COVID‐19 positive patient has higher postoperative mortality and morbidity,[^16^](#jso26174-bib-0016){ref-type="ref"} hence many hospitals recommend preoperative testing. Testing is aptly suited for major and prolonged surgeries, those involving aerosol‐generating procedures or having higher morbidity like pancreatic surgery. As expected, due to the fast rates doubling rates of infection the preoperative testing was done more in tier‐1 (*P* \< .001), the red zones (*P* = .06), and academic institutes (*P* = .057) as compared with tier‐3, green, and nonacademic institutes.

In the paucity of an accurate investigation to diagnose this infection with certainty, adequate PPE is paramount, especially in high‐risk cases. The N95 respirators mask is recommended for high‐risk procedures by the Centers for Disease Control and Prevention of United States[^17^](#jso26174-bib-0017){ref-type="ref"} and China.[^18^](#jso26174-bib-0018){ref-type="ref"} In our study, exclusive use of N95 respirators for all surgeries was seen in only 15%, however, the entire surgical team at MD Anderson Cancer Hospitals[^19^](#jso26174-bib-0019){ref-type="ref"} used N95 respirators for surgeries of the aero‐digestive tract. There is a global shortage of PPE and hence decontamination procedures have been described[^20^](#jso26174-bib-0020){ref-type="ref"} to circumvent this problem. Given that COVID‐19 can be transmitted through body fluids and aerosols that are generated during procedure,[^21^](#jso26174-bib-0021){ref-type="ref"} impermeable gowns are recommended as part of PPE.[^22^](#jso26174-bib-0022){ref-type="ref"} We noted only a small proportion of the surgeons used impermeable gowns (30%) routinely. Therefore, regular surgical gowns and regular surgical masks seem inadequate to venture into high‐risk surgeries. We also saw PPE shortage for the entire surgical team. This is a matter of concern as a small breach can lead to disruption of services.

Breast, HN, gynecology, and colorectal oncology formed the major chunk of oncologic work in India, in agreement with the results of Shrikhande et al.[^23^](#jso26174-bib-0023){ref-type="ref"} Major surgeries in HPB, CRS/HIPEC, and thoracic oncology are resource‐intense procedures with perspectives of PPE use, critical care support, and blood blank supplies, hence we observed that oncosurgeons were reluctant to operate such cases.

Concerns have been raised in MIS due to the isolation of viral particles in plumes of cautery. However, no transmission of infection has been documented through the smoke. Use of high‐efficiency particulate air filters, low intra‐abdominal pressures during surgery, minimal usage of energy devices, small port sizes, and evacuation of gases before the extraction of the specimen have been recommended.[^24^](#jso26174-bib-0024){ref-type="ref"} This concern was seen across all the oncosurgeons in our study with a decrease in MIS cases in agreement with the results of Shrikhande et al.[^23^](#jso26174-bib-0023){ref-type="ref"}

Telemedicine options are being explored by many hospitals to maintain the continuum of care, especially for oncologic surveillance. Being a resource centered project, private and hospitals in tier‐1 cities used telemedicine for cancer surveillance and patient care. Also, telemedicine focuses on patient\'s capabilities to use digital health services which may be limited in tier‐2/3 due to poverty and illiteracy in a developing country.

We propose a "FREE" corridor similar to "GREEN" corridors which are established for an organ transplant. This free corridor shall be a cleared‐out route with special permission during lockdown for cancer patients and health care workers to use public/private transport to reach the destined hospital. In this study, we noted that the majority of the cancer hospitals are located in tier‐1, which are the red zones. Consequently, this can transmit the infection from a high‐risk zone to low‐risk zones. This can be overcome by the "DECENTRALISATION" of cancer care. Decentralization would allow cancer care to be within reach of every individual providing additional financial and social security to the patients. We understand that decentralization is a long‐drawn process and has political, administrative, and financial connotations.

Finally, surgeons have adapted well to the pandemic by embracing telemedicine, PPE, judiciously using the surgical approach, reconstructive options, and human and hospital resources to provide cancer care. Hospitals adapted by creating COVID‐19 committees, dedicated wards, ICUs, and ORs to separate the patients of COVID‐19 and others. They also provided transportations and paid leaves at the time of the lockdown, although the facilities widely varied across institutes.

4.1. Strengths of the study {#jso26174-sec-0180}
---------------------------

To the best of our knowledge, it is the largest survey (256 oncologists) with a specialist surgical discipline exclusively dealing with cancer at the time of pandemic. The survey was pan‐India encompassing more than 206 cancer hospitals in 85 cities (Figure [2](#jso26174-fig-0002){ref-type="fig"}), giving a more holistic view of the situation across the country. Our study also highlights the well‐being of the oncologists in these unusual times.

![Map showing the geographical distribution of oncosurgeons who participated in the study across India. Red (circle), orange (square), and green (triangle) zones have been represented with respective colors \[Color figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)\]](JSO-9999-na-g002){#jso26174-fig-0002}

The limitations include the cross‐sectional nature of the study and does not capture the resumption of cancer care in India. This study of oncology care is entirely from a surgeon\'s perspective; medical oncologists, and radiation oncologists were excluded.

New challenges will emerge as pandemic evolves into community transmission and also in the postpandemic era to clear the backlog of the cases. However, there is uncertainty about the duration of the pandemic until a vaccine gives a breakthrough.

5. CONCLUSION {#jso26174-sec-0190}
=============

While the COVID‐19 pandemic had significantly disrupted cancer care across the country during the early months, a major proportion of the cancer hospitals quickly adapted to the changing circumstances and have implemented appropriate strategies to continue the cancer care. Despite limited resources, the significant risks associated, and financial setbacks amidst nationwide lockdown, oncosurgeons are striving to prioritize and balance the oncologic needs and safety concerns of cancer patients across the country. The oncosurgeons and hospitals will have to continue to adapt to the evolving pandemic for uninterrupted quality cancer care.
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This online cross‐sectional survey showed the disruption of cancer care in India. Hospitals have implemented strategies to continue cancer care. Despite limited resources, the significant risk associated and financial setbacks oncosurgeons are striving to prioritize and balance the oncologic and safety needs of patients with cancer.
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Number (%)Tier‐1 vs Tier‐2 vs Tier‐3 (n \[%\], *P* value)Government vs private vs mixed sector vs NGO (n \[%\], *P* value)Academic vs nonacademic centres (n \[%\], *P* value)Red zone vs orange zones vs green zones (n \[%\], *P* value)Dedicated cancer vs multispecialty centre (n \[%\], *P* value)Out‐patient servicesSuspended cancer screening118 (48.4)66 (56.9) vs 38 (42.7) vs 14 (35.9), *P* = .03121 (50) vs 88 (49.4) vs 2 (28.6) vs 7 (41.2), *P* = .66569 (46.6) vs 49 (51), *P* = .580 (57.7) vs 29 (38.2) vs 9 (32.1), *P* = 0.00544 (51.2) vs 74 (46.8), *P* = .518Follow‐up cases203 (80.6)96 (78) vs 71 (79.8) vs 36 (90), *P* = .2436 (83.7) vs 148 (80.4) vs 4 (57.1) vs 15 (83.3), *P* = .421119 (77.8) vs 84 (84.8), *P* = .166113 (77.9) vs 62 (80.5) vs 28 (93.3), *P* = 0.15270 (82.4) vs 133 (79.6), *P* = .60New cases244 (96.1)177 (93.6) vs 88 (98.9) vs 39 (97.5), *P* = .2139 (90.7) vs 181 (97.3) vs7 (100) vs 17 (94.4), *P* = .21148 (96.1) vs 96 (96), *P* = .96140 (95.2) vs 74 (96.1) vs 30 (100), *P* = 0.4784 (97.7) vs 160 (95.2), *P* = .345Telemedicine182 (72.2)99 (79.8) vs 57 (64) vs 26 (66.7), *P* = .02827 (61.4) vs 143 (77.3) vs 4 (66.7) vs 8 (47.1), *P* = .015118 (76.6) vs 64 (65.3), *P* = .051111 (76) vs 49 (64.5) vs 22 (73.3), *P* = .18847 (56) vs 135 (80.4), *P* \< .001Oncology practicesNonavailability of staging investigations177 (70)88 (70.4) vs 63 (71.6) vs 26 (65), *P* = .727 (61.4) vs 130 (70.7) vs 7 (100) vs 13 (72.2), *P* = .20100 (64.1) vs 77 (79.4) *P* = .01105 (71.9) vs 52 (67.2) vs 20 (66.7), *P* = .7262 (72.9) vs 115 (68.5), *P* = .46Some difficulty in getting endoscopy171 (68.7)89 (73) vs 53 (60.9) vs 29 (72.5) *P* = .1531 (73.8) vs 123 (67.6) vs 6 (85.7) vs 11 (61.1), *P* = .599 (64.7) vs 72 (75), *P* = .08101 (70.6) vs 50 (65.8) vs 20 (66.7), *P* = .7357 (67.1) vs 114 (69.5), *P* = .6Difficulty in finding microvascular surgeon93 (40.8)41 (35.7) vs 31 (40.3) vs 21 (58.3), *P* = .0518 (48.6) vs 65 (38) vs 3 (75) vs 4 (43.8), *P* = .3246 (32.9) vs 47 (53.4), *P* = .00254 (40.6) vs 30 (44.8) vs 9 (32.1), *P* = .5230 (39.5) vs 63 (41.4), *P* = .77Operate inadequately staged patient39 (16)15 (12.5) vs 18 (20.9) vs 6 (15.4) *P* = .279 (22) vs 28 (15.6) vs 1 (16.7) vs 1 (5.6) *P* = .4621 (14.3) vs 18 (18.6) *P* = .3725 (17.5) vs 11 (15.1) vs 3 (10.7), *P* = .6412 (14.3) vs 27 (16.9), *P* = .60Avoiding tracheostomy due to risk of aerosolization42 (20.5)19 (20.2) vs 15 (20) vs 8 (20), *P* = .969 (28.1) vs 28 (18.1) vs 1 (25) vs 4 (28.6), *P* = .5023 (19.3) vs 19 (22.1), *P* = .6223 (19.3) vs 13 (21.7) vs 6 (23.1), *P* = .8814 (18.2) vs 28 (21.9), *P* = .52Continue microvascular reconstruction121 (60.2)58 (61.7) vs 46 (60.5) vs 17 (54.8), *P* = .7311 (40.7) vs 99 (63.9) vs 5 (100) vs 6 (42.9), *P* = .01774 (63.2) vs 47 (56), *P* = .2972 (60.5) vs 34 (59.6) vs 15 (60), *P* = .9948 (66.7) vs 73 (56.6), *P* = .16Practice pedicle flaps over free flap116 (59.2)52 (56.6) vs 44 (61.1) vs 20 (62.5), *P* = .76916 (66.7) vs 88 (57.5) vs 3 (75) vs 9 (60), *P* = .76562 (54.9) vs 54 (65.1), *P* = .1572 (61.5) vs 32 (57.1) vs 12 (52.2), *P* = .640 (56.3) vs 76 (60.8), *P* = .54Defer surgery (if NACT has good response)93 (38.4)51 (42.9) vs 30 (34.5) vs 12 (33.3), *P* = .3722 (52.4) vs 65 (36.3) vs 1 (16.7) vs 5 (33.3), *P* = .1659 (39.1) vs 34 (37.4), *P* = .7962 (43.7) vs 23 (32.4) vs 8 (27.6), *P* = .12422 (26.8) vs 71 (44.4), *P* = .008Defer adjuvant RT/Chemotherapy (only if there is marginal benefit)76 (32.3)41 (36) vs 25 (28.4) vs 10 (30.3), *P* = .520 (51.3) vs 49 (27.8) vs 1 (20) vs 6 (40), *P* = .0353 (36.6) vs 23 (25.6), *P* = .0842 (30.7) vs 27 (38) vs 7 (25.9), *P* = .4228 (34.1) vs 48 (31.4), *P* = .6Defer treatment of preinvasive disease139 (60.7)72 (64.9) vs 47 (55.3) vs 20 (60.6), *P* = .3730 (76.9) vs 98 (57.3) vs 1 (25) vs 10 (66.7), *P* = .5886 (61.5) vs 53 (58.9), *P* = .65283 (61.5) vs 46 (67.6) vs 10 (38.5), *P* = .03347 (58.8) vs 92 (61.7), *P* = .65PPE for high‐risk surgeryN95 respirator229 (94.2)113 (95.8) vs 78 (90.7) vs 38 (97.4), *P* = .19939 (95.1) vs 170 (94.4) vs 5 (100) vs 15 (88.2), *P* = .681140 (95.9) vs 89 (91.9), *P* = .175133 (93.7) vs 70 (95.9) vs 26 (92.9), *P* = .75981 (96.4) vs 148 (93.1), *P* = .20Surgical mask185 (78.1)93 (83) vs 61 (70.1) vs 31 (81.6), *P* = .07827 (73) vs 142 (79.8) vs 5 (100) vs 11 (64), *P* = .2112 (80.6) vs 73 (74.5), *P* = .265109 (80.1) vs 56 (78.9) vs 20 (66.7), *P* = .26668 (84) vs 117 (75), *P* = .114PAPR66 (28.9)39 (36.4) vs 17 (20) vs 10 (27.8), *P* = .04410 (27) vs 53 (31.4) vs 0 vs 3 (17.6), *P* = .339 (30) vs 27 (27.6), *P* = .6839 (29.1) vs 15 (22.7) vs 12 (42.9), *P* = .4420 (25.6) vs 46 (30.7), *P* = .427Regular surgical gown131 (56.5)56 (50) vs 55 (64.7) vs 20 (57.1), *P* = .11920 (54.) vs 96 (55.8) vs 4 (66.7) vs 11 (64.7) *P* = .874 (55.2) vs 57 (58.2), *P* = .6569 (50.4) vs 42 (63.6) vs 20 (69), *P* = .6749 (62) vs 82 (53.6), *P* = .22HIV protection kit169 (73.2)81 (73) vs 61 (73.5) vs 27 (73) *P* = .99628 (71.8) vs 123 (72.4) vs 4 (80) vs 14 (82.4), *P* = .8198 (72.6) vs 71 (74), *P* = .8199 (73.9) vs 51 (73.9) vs 19 (67.9) *P* = .7955 (69.6) vs 114 (75), *P* = .38Suit for COVID‐19122 (51.7)67 (58.3) vs 33 (39.3) vs 22 (59.5), *P* = .01819 (48.7) vs 89 (50.6) vs 4 (80) vs 10 (62.5) *P* = .4674 (52.5) vs 48 (50.5) *P* = .7674 (53.6) vs 36 (50.7) vs 12 (44.4), *P* = .6732 (39) vs 90 (58.4), *P* = .004Face shield220 (90.2)113 (96.6) vs 72 (82.8) vs 35 (87.5), *P* = .00438 (92.7) vs 160 (88.9) vs 6 (100) vs 16 (94), *P* = .665135 (93.1) vs 85 (85.9), *P* = .06133 (93.7) vs 63 (87.5) vs 24 (80), *P* = .04978 (90.5) vs 144 (90), *P* = .906Adequacy of PPE for the surgical teamPPE for anesthetist211 (88.3)110 (94.8) vs 71 (83.5) vs 30 (78.9), *P* = .00736 (90) vs 153 (86.4) vs 5 (100) vs 17 (100), *P* = .30130 (91.5) vs 81 (83.5), *P* = .058127 (92) vs 60 (83.3) vs 24 (82.9), *P* = .1070 (85.4) vs 141 (89.8), *P* = .31PPE for scrub nurse208 (86.7)107 (92.2) vs 71 (82.6) vs 30 (78.9), *P* = .04235 (87.5) vs 152 (85.4) vs 5 (100) vs 16 (94.1), *P* = .60129 (90.2) vs 79 (81.4), *P* = .05128 (92.1) vs 56 (77.8) vs 24 (82.8), *P* = .01269 (84.1) vs 139 (88), *P* = .40PPE for the surgical assistant213 (89.1)110 (94.8) vs 72 (84.7) vs 31 (81.6), *P* = .0236 (90) vs 155 (87.6) vs 5 (100) vs 17 (100) *P* = .368132 (92.4) vs 81 (84.4), *P* = .05128 (92.8) vs 60 (83.3) vs 25 (86.2), *P* = .0972 (88.9) vs 141 (89.2), *P* = .934Functioning of radiotherapy unitsRT centre shut down9 (5.1)4 (4.7) vs 2 (3.2) vs 3 (10.3), *P* = .0154 (11.4) vs 4 (3.1) vs 1 (25) vs 0, *P* = .036 (5.6) vs 39 (4.2), *P* = .86 (5.7) vs 2 (3.7) vs 1 (5.3), *P* = 0.41 (1.8) vs 8 (6.5), *P* = .15Increased waitlist at RT centre52 (26.9)19 (19.4) vs 19 (29.2) vs 14 (46.7), *P* \< .00122 (57.9) vs 29 (20.7) vs 1 (25) vs 0, *P* \< .00135 (30.4) vs 17 (21.8), *P* = .2430 (26.1) vs 18 (32.1) vs 4 (18.2), *P* = 0.4918 (28.6) vs 34 (26.2), *P* = .46Hypo fractionated regimen followed66 (35.1)38 (40.4) vs 20 (30.8) vs 8 (27.6), *P* = .04811 (30.6) vs 51 (37) vs 1 (25) vs 3 (30) *P* = .06945 (38.1) vs 21 (30), *P* = .2845 (40.2) vs 16 (29.1) vs 5 (23.8), *P* = 0.224 (40) vs 42 (32.8), *P* = .05Palliative RT163 (78.7)72 (72) vs 62 (86.1) vs 29 (82.9), *P* = .02528 (68.3) vs 123 (82) vs 2 (50) vs 10 (83.3) *P* = .03898 (76.6) vs 65 (82.3), *P* = .591 (76.5) vs 53 (81.5) vs19 (82.6), *P* = .8361 (88.4) vs 102 (73.9), *P* = .016Employee well‐beingWork in rotation108 (47)64 (58.7) vs 30 (35.7) vs 14 (37.8), *P* = .00330 (71.4) vs 65 (39.2) vs 5 (83.3) vs 8 (50), *P* = .00182 (57.7) vs 26 (29.5) *P* \< .00168 (51.9) vs 26 (36.6) vs 14 (50), *P* = .1042 (50.6) vs 66 (44.9), *P* = .4Provision of paid leave for surgeons68 (30.1)32 (29.6) vs 23 (28) vs 13 (36.1), *P* = .720 (46.5) vs 41 (25.3) vs 2 (33) vs 5 (33.3), *P* = .2048 (33.6) vs 20 (24.1), *P* = .3231 (24.2) vs 28 (40.6) vs 9 (31), *P* = .07431 (38.3) vs 37 (25.5), *P* = .13Provision for daily transportation168 (68)88 (71.5) vs 59 (67) vs 21 (58.3), *P* = .2825 (59.5) vs 127 (70.2) vs 5 (83.3) vs 11 (61.1), *P* = .36109 (72.7) vs 59 (60.8), *P* = .00499 (67.8) vs 46 (63) vs 23 (82.1), *P* = .3852 (61.9) vs 116 (71.2), *P* = .11Deduction in salary122 (47.7)57 (44.9) vs 47 (52.8) vs 18 (45), *P* = .4815 (34.1) vs 101 (54) vs 1 (14.3) vs 5 (27.8), *P* = .00767 (42.9) vs 55 (55), *P* = .0617 (56.7) vs 35 (45.5) vs 70 (47), *P* = .542 (48.8) vs 80 (47.1), *P* = .78[^1]John Wiley & Sons, Ltd.This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.

[^1]: Abbreviations: COVID, coronavirus disease; NACT, neoadjuvant chemotherapy; PAPR, powered air‐purifying respirator; RT, radiotherapy.
